References
- Arctic Vision announces US$32MN in Series A to expand and develop innovative therapies pipeline in ophthalmology. www.prnewswire.com/news-releases/arctic-vision-announces-us32mn-in-series-a-to-expand-and-develop-innovative-therapies-pipeline-in-ophthalmology-301092594.html
- Sorrel Medical opens manufacturing facility for wearable drug delivery. www.prnewswire.com/il/news-releases/sorrel-medical-opens-new-manufacturing-facility-increasing-clinical-and-commercial-supply-capabilities-of-wearable-drug-delivery-devices-301088997.html
- Wearable drug delivery provider Sorrel Medical partners with leading Global Pharmaceutical Manufacturer. www.prnewswire.com/il/news-releases/wearable-drug-delivery-provider-sorrel-medical-partners-with-leading-global-pharmaceutical-manufacturer-301096978.html#:∼:text=NETANYA,%20Israel,%20July%2021,to%20advance%20the%20development%20and
- Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies. www.news-medical.net/news/20200723/Vesigen-Therapeutics-to-develop-and-commercialize-novel-drug-delivery-technologies.aspx
- Avanti Polar Lipids agrees to be acquired by Croda. www.pharmiweb.com/press-release/2020-07-06/avanti-polar-lipids-agrees-to-be-acquired-by-croda
- Princeton's Prud'homme and Yang partner with Genentech to decode a key process in vaccines and cancer treatments. www.princeton.edu/news/2020/07/31/princetons-prudhomme-and-yang-partner-genentech-decode-key-process-vaccines-and
- Foresee Pharmaceuticals announces submission of NDA for FDA approval of LMIS 50 mg. www.prnewswire.com/news-releases/foresee-pharmaceuticals-announces-submission-of-nda-for-fda-approval-of-lmis-50-mg-301100742.html
- Heron Therapeutics receives positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the management of postoperative pain. www.prnewswire.com/news-releases/heron-therapeutics-receives-positive-chmp-opinion-for-zynrelef-htx-011-for-the-management-of-postoperative-pain-301099292.html
- Phase III data show Roche's Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration. www.globenewswire.com/news-release/2020/07/22/2066026/0/en/Phase-III-data-show-Roche-s-Port-Delivery-System-with-ranibizumab-enabled-over-98-of-patients-to-go-six-months-between-treatments-for-neovascular-age-related-macular-degeneration.html
- SINOMED® Completes one-year follow-up of the PIONEER-III European, US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent. www.prnewswire.com/news-releases/sinomed-completes-one-year-follow-up-of-the-pioneer-iii-european-us-and-japanese-trial-of-the-buma-supreme-coronary-drug-eluting-stent-301091664.html
- Oramed reports positive end of Phase II meeting with the FDA for oral insulin. www.prnewswire.com/news-releases/oramed-reports-positive-end-of-phase-2-meeting-with-the-fda-for-oral-insulin-301093920.html
- Abeona therapeutics reinitiates enrollment in EB-101 Pivotal Phase III VIITAL™ Study in RDEB after COVID-19 related pause and announces progress in patient enrollment in MPS III studies. www.globenewswire.com/news-release/2020/07/08/2059181/0/en/Abeona-Therapeutics-Reinitiates-Enrollment-in-EB-101-Pivotal-Phase-3-VIITAL-Study-in-RDEB-after-COVID-19-Related-Pause-and-Announces-Progress-in-Patient-Enrollment-in-MPS-III-Studi.html
- Entera Bio Ltd provides update on Phase II clinical trial of EB613 in postmenopausal women with osteoporosis. www.globenewswire.com/news-release/2020/07/07/2058583/0/en/Entera-Bio-Ltd-Provides-Update-on-Phase-2-Clinical-Trial-of-EB613-in-Postmenopausal-Women-With-Osteoporosis.html
- REGENXBIO provides update on progress of clinical programs for rare genetic neurodegenerative diseases. www.prnewswire.com/news-releases/regenxbio-provides-update-on-progress-of-clinical-programs-for-rare-genetic-neurodegenerative-diseases-301089731.html
- Hoag implants first deep brain stimulation with BrainSense Technology for Parkinson's disease in California. www.prnewswire.com/news-releases/hoag-implants-first-deep-brain-stimulation-with-brainsense-technology-for-parkinsons-disease-in-california-301096466.html
- FDA approves Medtronic's Percept PC Deep Brain Stimulation System. https://parkinsonsnewstoday.com/2020/07/02/fda-approves-medtronic-percept-pc-deep-brain-stimulation-system-for-parkinsons/
- Arcturus Therapeutics & Duke-NUS received approval to proceed with Phase I/II clinical trial for COVID-19 Vaccine Candidate, LUNAR-COV19. www.globenewswire.com/news-release/2020/07/21/2064896/0/en/Arcturus-Therapeutics-Duke-NUS-Received-Approval-to-Proceed-with-Phase-1-2-Clinical-Trial-for-COVID-19-Vaccine-Candidate-LUNAR-COV19.html
- Spark Therapeutics announces updated data on SPK-8011 from Phase I/II clinical trial in Hemophilia A at ISTH 2020 Virtual Congress. www.globenewswire.com/news-release/2020/07/12/2060941/0/en/Spark-Therapeutics-Announces-Updated-Data-on-SPK-8011-from-Phase-1-2-Clinical-Trial-in-Hemophilia-A-at-ISTH-2020-Virtual-Congress.html
- MIT researchers think they've found a way to get more particles through a syringe. www.drugdeliverybusiness.com/mit-researchers-think-theyve-found-a-way-to-get-more-particles-through-a-syringe/
- Evox Therapeutics expands existing exosome patent portfolio with further grant covering exosomes for RNA therapeutics. www.prnewswire.com/news-releases/evox-therapeutics-expands-existing-exosome-patent-portfolio-with-further-grant-covering-exosomes-for-rna-therapeutics-301093231.html
- ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine nasal spray). www.prnewswire.com/news-releases/ars-pharmaceuticals-announces-new-patent-on-ars-1-epinephrine-nasal-spray-301091567.html